Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(RESONATE™) | completed | Phase 3 | 391 | Pharmacyclics LLC.INDUSTRY | 10 | Dec 18, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Dec 17, 2019 |
| clinicaltrials |
| NCT02186574 | Tenofovir to Prevent HBV Reactivation | unknown | Phase 3 | 184 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01197560 | Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 / Phase 3 | 111 | CelgeneINDUSTRY | 9 | Nov 25, 2019 | clinicaltrials |
| NCT00622336 | A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | completed | Phase 3 | 330 | CelgeneINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma(FIRST) | completed | Phase 3 | 1,623 | CelgeneINDUSTRY | 19 | Nov 20, 2019 | clinicaltrials |
| NCT00928486 | A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 25 | CelgeneINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).(RENEW) | terminated | Phase 3 | 9 | CelgeneINDUSTRY | 12 | Nov 19, 2019 | clinicaltrials |
| NCT01324947 | Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | completed | Phase 3 | 74 | CelgeneINDUSTRY | 15 | Nov 19, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT02811978 | Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 3 | 81 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00657488 | Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma | completed | Phase 2 / Phase 3 | 400 | CelgeneINDUSTRY | 2 | Oct 18, 2019 | clinicaltrials |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | completed | Phase 3 | 85 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00137995 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | completed | Phase 3 | 481 | Lymphoma Study AssociationOTHER | 10 | Aug 28, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | terminated | Phase 3 | 161 | Gilead SciencesINDUSTRY | 5 | Aug 20, 2019 | clinicaltrials |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 261 | Gilead SciencesINDUSTRY | 11 | Aug 14, 2019 | clinicaltrials |
| NCT00382109 | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | completed | Phase 3 | 146 | Children's Oncology GroupNETWORK | 3 | Aug 7, 2019 | clinicaltrials |
| NCT00004228 | Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma | completed | Phase 3 | 393 | Children's Oncology GroupNETWORK | 5 | Aug 6, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | completed | Phase 3 | 454 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 6 | Jun 6, 2019 | clinicaltrials |
| NCT03777085 | Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) | unknown | Phase 3 | 230 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2019 | clinicaltrials |
| NCT02042690 | Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients | completed | Phase 3 | 131 | Peking UniversityOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT00262795 | Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 3 | 206 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT00275054 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 825 | German CLL Study GroupOTHER | 3 | May 23, 2019 | clinicaltrials |
| NCT00276848 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia | completed | Phase 3 | 375 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 3 | 244 | Peking UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00003280 | Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma | completed | Phase 3 | 240 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00227695 | Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 270 | Swiss Cancer InstituteOTHER | 7 | May 15, 2019 | clinicaltrials |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 220 | Gilead SciencesINDUSTRY | 5 | May 14, 2019 | clinicaltrials |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | terminated | Phase 3 | 1,418 | Hoffmann-La RocheINDUSTRY | 29 | Apr 12, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT00646854 | Alemtuzumab and CHOP in T-cell Lymphoma(ACT-1) | completed | Phase 3 | 136 | Aarhus University HospitalOTHER | 11 | Mar 1, 2019 | clinicaltrials |
| NCT00928018 | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma | completed | Phase 3 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02145598 | Treatment Optimization in Patients With Untreated Multiple Myeloma(GERMAIN) | terminated | Phase 2 / Phase 3 | 85 | Dr. med. Lars-Olof MueggeOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT02767674 | Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | Phase 3 | 258 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03792620 | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation(MAXDARA) | unknown | Phase 3 | 20 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01987505 | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma | completed | Phase 3 | 140 | Hoffmann-La RocheINDUSTRY | 1 | Dec 26, 2018 | clinicaltrials |
| NCT01470131 | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | terminated | Phase 3 | 147 | AB ScienceINDUSTRY | 2 | Dec 19, 2018 | clinicaltrials |
| NCT03355768 | Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | withdrawn | Phase 3 | 0 | Jennifer AmengualOTHER | 0 | Dec 19, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 57 | Gilead SciencesINDUSTRY | 8 | Nov 19, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2019source: clinicaltrials